NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced it is developing its first adeno-associated ...

Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...